Hydrofarm Announces Reverse Stock Split — Neutral

HYFM   GlobeNewsWire — February 10, 2025

SHOEMAKERSVILLE, Pa., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (Nasdaq: HYFM) (“Hydrofarm” or the “Company”) today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on February 12, 2025. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on February 13, 2025, under the Company's existing trading symbol “HYFM.”

image for news Hydrofarm Announces Reverse Stock Split

Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer — Neutral

IOVA   GlobeNewsWire — February 10, 2025

SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership team in the newly created role of Chief Commercial Officer, effective today.

image for news Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

Glass Lewis Finds Matthews Has "Persistently Deteriorated and Consistently Underperformed During Substantially All Measurement Periods, Including During the Fullness of Mr. Bartolacci's Tenure as CEO" Asserts Barington "Has Offered Investors a Reasonable, Credible and Incremental Slate of Candidates" and a "More Promising Roadmap" for the Company Recommends Shareholders Vote "WITHHOLD" on Matthews' Nominees Terry L.

image for news Leading Proxy Advisory Firm Glass Lewis Joins ISS and Egan-Jones in Recommending Matthews International Shareholders Vote the GOLD Proxy Card "FOR" ALL of Barington Capital's Nominees: Ana Amicarella, Chan Galbato and James Mitarotonda

McDONALD'S REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS — Neutral

MCD   PRNewsWire — February 10, 2025

Global Systemwide sales* were over $130 billion for the full year, with full year growth of more than $1 billion (more than $2 billion in constant currencies) Systemwide sales to loyalty members were approximately $30 billion for the full year and approximately $8 billion for the quarter across 60 loyalty markets, with full year growth of 30% over prior year 90-day active loyalty users were over 175 million across 60 loyalty markets as of year-end, with growth of approximately 15% over prior year CHICAGO , Feb. 10, 2025 /PRNewswire/ -- McDonald's Corporation today announced results for the fourth quarter and …

image for news McDONALD'S REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS

Beamr CEO will Present a Keynote Speech at the ACM Mile-High-Video 2025 — Neutral

BMR   GlobeNewsWire — February 10, 2025

The Keynote Titled ״Is the future of video processing destined for GPU?״ Describes First Hand The Evolution of Video Encoding in the Past Decades Herzliya Israel, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Beamr Imaging Ltd.

image for news Beamr CEO will Present a Keynote Speech at the ACM Mile-High-Video 2025

Streamlining the Referral Process to Enhance Efficiency and Patient Experience SOMERSET, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare technology and AI-driven solutions, is proud to announce the launch of its new advanced referral module.

image for news Up to 70% Time Savings Achieved with Fully Integrated Advanced Referral Module of CareCloud's AI-Enabled EHR

Gross Profit Increased 23.5% from the Previous Year to $7.7 million Gross Margins Increased to 18.5%, up from 15.0% the Previous Year Revenue Increased 0.3% Year-Over-Year to $41.8 Million LOS ANGELES , Feb. 10, 2025 /PRNewswire/ -- Ispire Technology Inc. ( NASDAQ: ISPR ) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal second quarter 2025, which ended on December 31, 2024. Fiscal Second Quarter 2025 Financial Results Revenue of $41.8 million, compared to $41.7 million for the fiscal second quarter of 2024.

image for news Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2025

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer — Neutral

NCNA   Business Wire — February 10, 2025

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO). “We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion's CEO. “Don's track record of strategic and operational financial leadership, coupled.

image for news Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Caribou securities between July 14, 2023 and July 16, 2024, both dates inclusive (the "Class Period").

image for news CRBU STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Nextracker Inc. ("Nextracker" or "the Company") (NASDAQ: NXT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Nextracker securities between February 1, 2024 and August 1, 2024, both dates inclusive (the "Class Period").

image for news NXT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nextracker Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Capri Holdings Limited ("Capri" or "the Company") (NYSE:CPRI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Capri securities between August 10, 2023 and October 24, 2024, both dates inclusive (the "Class Period").

image for news CPRI INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Capri Holdings Limited to Contact the Firm Today!

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").

image for news RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period").

image for news PCRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

SAN FRANCISCO , Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells (Tregs).

image for news Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Enphase Energy, Inc. ("Enphase" or "the Company") (NASDAQ:ENPH) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Enphase securities between April 25, 2023 and October 22, 2024, both dates inclusive (the "Class Period").

image for news FINAL ENPH DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Enphase Energy, Inc. Investors to Join the Class Action Lawsuit

WALTHAM, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, will be presenting at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

image for news Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Guardant Health to Participate in Upcoming Investor Conferences — Neutral

GH   Business Wire — February 10, 2025

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Hosting 1x1 meetings on Tuesday, February 11th and Wednesday, February 12th TD Cowen 45th Annual Health Care Conference in Boston, MA Fireside chat on Tuesday, March 4th at 10:30 a.m. Eastern Tim.

image for news Guardant Health to Participate in Upcoming Investor Conferences

PetMed Express: Dip Or Rip, A Buy After Earnings — Positive

PETS   Seeking Alpha — February 10, 2025

PetMed Express stock could surge or sink after this week's quarterly earnings release, but don't read too much into this near-term event. A disappointing earnings release won't necessarily shatter the bull case, and could, in fact, push this stock back down to "back up the truck" price levels. Conversely, even if PETS rallies on strong results, this may not capture all of the potential long-term upside.

image for news PetMed Express: Dip Or Rip, A Buy After Earnings

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Announces Positive Topline Results for Breyanzi in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma.

image for news Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

Oil prices shake off tariff worries to rise after 3 straight weekly declines — Positive

BNO  DBO  GUSH  IEO  OIH  OIL  PXJ  UCO  USO  XOP   Market Watch — February 10, 2025

Oil futures rose Monday, finding support after three straight weekly declines that took crude to its lows of the new year.

image for news Oil prices shake off tariff worries to rise after 3 straight weekly declines